Purpose: To investigate the effectiveness and tolerability of topiramate (TPM) in treating children with CNS anomalies and intractable epilepsy. Methods: We retrospectively searched the patient database in National Taiwan University Hospital for candidate children (younger than 18 years of age) with epilepsy and CNS anomalies from December 2002 to February 2004. The effectiveness and possible side effects of TPM were evaluated by questionnaire. Results: Twenty-two children (9 males, 13 females) aged from five months to fourteen years were enrolled in the present study. Underlying CNS anomalies were proliferation disorders (n=10), migration/organization disorders (n=10), and neurocutaneous syndromes (n=2). Types of epilepsy at TPM add-on were symptomatic partial epilepsy (n=11), infantile spasms (n=7), and Lennox-Gastaut syndrome (n=4). During the follow-up periods of six to 30 months, eight patients (36%) had more than 50% reduction of seizures and four patients (18%) were seizure-free. The average dosages 
Introduction
CNS anomalies, especially those involving the cerebral cortex, are usually associated with epilepsy [1, 2] . Patients with CNS anomalies frequently suffer from intractable epilepsy. For example, almost 100% of patients with hemimegalencephaly or subcortical heterotopia have epilepsies, many of which are intractable [1] . With the development of newer antiepileptic drugs (AED), more and more intractable seizures can be controlled by new AEDs. Few reports, however, focus on the efficacy of these new AEDs on this group of patients. Topiramate (TPM), a newer AED, has been recognized to influence several biochemical/ pharmacologic activities in the nervous system, including (a) blockade of voltagedependent sodium channels in the neuronal membrane; (b) negative modulatory effect at kainite α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate (AMPA) glutamate receptors; (c) enhancement of γ-aminobutyric acid (GABA) activity at GABA A receptors; and (d) inhibition of carbonic anhydrase isoenzymes (isoenzymes II and IV more than others) [3, 4] . Twenty-two studies evaluating its clinical efficacy were available in the literature from 1996 to 2002 [5] . TPA has been proven to be effective as an adjunctive AED for partial seizures [6] , primary generalized seizures (including infantile spasms and absence epilepsy) [7] [8] [9] , and Lennox-Gastaut syndrome [10] . TPM has also been shown to be effective in the treatment of epilepsy in patients with Angelman syndrome and learning disability [11] . Its effect in patients with CNS anomalies, however, has never been investigated. This is a pilot study of TPM use in children with CNS anomalies, to evaluate if TPM is a promising add-on therapy for this patient population.
Patients and Methods

Patients
We retrospectively searched the patient database in National Taiwan University Hospital for children (age less than 18 years old) with epilepsy and CNS anomalies between December 2002 and February 2004. There were 3,062 patients with convulsions (780.3, ICD-9) or epilepsy (345, ICD-9). After investigating their chart records, 431 patients were confirmed to have epilepsy. Three patients with epilepsy did not take any AED because of either the parents' refusal or loss to follow-up. Fifty-two of 428 epileptic patients taking AEDs had TPM in their medication. Because brain biopsy for histological examination and classification was often unavailable in clinical practice [12] , CNS anomalies in this study were classified by neuroimaging and clinical criteria. All patients' clinical data, including birthday, sex, seizure types, EEG findings, neuroimaging results and AEDs, were derived from their medical records. Patients with infectious diseases, neoplasms, metabolic disorders, degenerative diseases and hypoxicischemic encephalopathy were excluded. Seizure types were classified according to the International Classification of Epileptic Seizures (ILAE, 1981) [13] . The epilepsies were classified according to the proposed classification of epilepsies and epileptic syndromes (ILAE, 1989) [14] . Informed consent was obtained from a responsible caregiver of each patient.
TPM therapy
All received TPM as an add-on therapy for their difficult-to-control epilepsies. The starting dose of TPM was 0.5-1 mg/kg/day. Then it was increased gradually up to 9 mg/kg/day or when seizures stopped, with weekly increment of 1-2 mg/kg/day. In cases of infantile spasms, TPM was titrated up to 25 mg/kg/day or when seizures stopped [8, 15] .
Evaluation
The effectiveness and possible side effects of TPM were evaluated by a questionnaire during the study period. The seizure reduction and side effects observed only during treatment with TPM and fixed concomitant AEDs were recorded. The efficacy of TPM was presented as the proportion of responders (seizure-free and more than 50% reduction in seizure frequency) and major responsive seizure types. The authors inquired every patient or his/her parent directly either by interview at our outpatient clinic or by telephone.
Besides, considering the increasing importance of effects of AEDs on health-related quality of life, we actively inquired effects on alertness, sleep, appetite, emotion and behavior in addition to seizure reduction, and graded them on a five-point scale: much better (1), better (2), the same (3), worse (4), or much worse (5) . As for the treatment-emergent adverse effects, the checklist was summarized from literature reviews. Each item is rated on a 3-point scale for presence (marked, mild, and none). If the adverse effect was easily and frequently noticed, it was rated as 'marked'; otherwise, 'mild' for trivial and infrequent adverse effects. We actively inquired all parents about all the adverse effects one by one, instead of asking them to self-report.
Results
Twenty-two children (9 males and 13 female) with CNS anomalies and intractable epilepsies treated with TPM were enrolled ( Table 1 ). The numbers of AEDs taken by the patients before adding TPM were three in seven (32%), two in seven (32%), and one in eight (36%). The seizure frequencies were more than once per day in 15 (68%), more than once per week in four (18%), more than once per month in two (9%), and less than once per month in one (5%). Ages at TPM add-on therapy ranged from five months to fourteen years. CNS anomalies included proliferation disorders (n=10, patients 1-10), migration or organization disorders (n=10, patients [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , and neurocutaneous syndromes (n=2, patients [21] [22] . Types of epilepsies at TPM add-on therapy were symptomatic partial epilepsies (SPE) (n=11), infantile spasms (IS) (n=7), and Lennox-Gastaut syndrome (LGS) (n=4). Eight of eleven patients with SPE had secondarily generalized seizures, and the remaining three patients had only focal seizures. Evolutional changes of epilepsies were noted in eight patients: IS evolving to LGS (n=4), early infantile epileptic encephalopathy (EIEE) evolving to IS (n=1), neonatal seizures evolving to IS (n=2), and EIEE evolving to SPE (n=1). The average dosages of TPM ranged from 2.5 to 25 mg/kg/day. The durations of follow-up after adding TPM ranged from 6 to 30 months. Seven patients (32%) became free of seizures within three months of TPM therapy; four (18%) remained seizure-free after six months. Eight patients (36%) had more than 50% of seizure reduction. Therefore, the percentage of responders was 54%. Three patients (14%) had less than 50% reduction of seizure frequency. Seven patients (32%) showed no response to TPM. The seizures aggravated in two patients (9%). Proliferation disorders responded better than migration disorders and neurocutaneous syndromes (responder rates, 80% vs. 40% and 0% respectively; Fischer's exact test, p < 0.05) (Figure 1 ).
Responses of respective epilepsies and seizures
After follow-up for more than six months, three of 11 (27%) patients with SPE were free of seizures and four (36%) had more than 50% reduction of seizures ( Figure 2) . One of seven (14%) patients with IS were free of seizures, TPM in epileptic children with CNS anomalies Wang-Tso Lee, et al. Figure 1 . Responses of underlying CNS anomalies to TPM therapy. Different CNS anomalies responded differently to TPM therapy. Eighty percent of patients with CNS proliferation disorders and epilepsies had more than 50% of seizure reduction, while 40% of patients with migration disorders did. Both patients with neurocutaneous syndromes did not respond to TPM therapy. and four (57%) had more than 50% reduction of seizures. None of the patients with LGS had more than 50% reduction of seizure frequency after long-term follow-up. Patient 17, a patient of Miller-Dieker syndrome and LGS, was initially free of seizures after adding TPM, but seizures recurred ten months later and became intractable. Her seizures decreased more than 50% after starting ketogenic diet. For better comparison with previous reports, symptomatic generalized epilepsies (including IS and LGS, n=11), secondarily generalized epilepsies (eight of 11 patients with SPE) and other SPE (the remaining three patients with SPE) were further analyzed. One of 11 (9%) patients with symptomatic generalized epilepsies were free of seizures; four (36%) had more than 50% reduction of seizures; and four (36%) showed no response. One of eight (13%) patients with secondarily generalized epilepsies was free of seizures, while three (38%) had more than 50% reduction of seizures. Two of three (67%) patients with other SPE were free of seizures, while the remaining one (33%) had more than 50% reduction of seizures. The most responsive seizure types were generalized tonic-clonic seizures (n=6), myoclonic seizures (n=5), tonic seizures (n=5), atonic seizures (n=2), and complex partial seizures (n=1).
Concomitant AEDs
Before adding on TPM, all patients took one to three kinds of AEDs, including phenobarbital, carbamazepine, valproic acid, phenytoin, clonazepam, vigabatrin, lamotrigine, and primidone. There was no statistically significant difference between the re- Responses of different epilepsies to TPM therapy. Infantile spasms and symptomatic partial epilepsy responded better to TPM therapy than Lennox-Gastaut syndrome. Seventy-one percents of patients with infantile spasms had more than 50% of seizure reduction, while all patients with Lennox-Gastaut syndrome had less than 50% seizure reduction. IS, infantile spasms; LGS, Lennox-Gastaut syndrome; SPE, symptomatic partial epilepsy. sponder (n=12) and the non-responder (n=10) groups with respect to the number of AEDs used before TPM add-on, (Mann-Whitney test). Nine patients with less than 50% reduction of seizures after TPM therapy received additional AEDs (including vigabatrin, clonazepam, lamotrigine) to strengthen seizure control and achieved partial response.
Recurrence of seizures
Only three patients (Patient 5, 12 and 17) had seizure recurrence in one year after TPM add-on therapy. Patient 5 was free of GTC after TPM therapy. One month later, unfortunately, focal seizures developed. After increasing dosage of TPM from 3 to 6 mg/kg/ day, his condition stabilized again. Patient 12 became free of tonic seizures after adding TPM to valproic acid. Tonic seizures recurred after tapering valproic acid. Patient 17, a patient of Miller-Dieker syndrome and LGS, had seizure recurrence ten months after TPM therapy.
Health-related quality of life
As for the effect of TPM on various parameters of health-related quality of life, no apparent impact was noted in 77% of patients on alertness, 86% on sleep, 73% on appetite, 82% on emotion control and 82% on behavior control ( Figure 3 ). Improvements were noted in 18% of patients on alertness, 9% on sleep, 10% on appetite, 9% on emotion control and 5% on behavior control: the most favorable aspect was alertness. Deteriorations were noted in 5% of patients on alertness, 5% on sleep, 19% on appetite, 9% on emotion control and 14% on behavior control: appetite distur-
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Wang-Tso Lee, et al. Figure 3 . Effects of TPM add-on therapy on various parameters of quality of life. TPM therapy had no adverse impact on alertness, sleep, appetite, emotional and behavior control of most patients. In total, more than half of our patients felt better in their daily life after adding TPM. No response EIEE = early infantile epileptic encephalopathy; GTC = generalized tonic-clonic; IS = infantile spasms; LGS = Lennox-Gastaut syndrome; SPE = symptomatic partial epilepsy; * = Epilepsy type at TPM add-on therapy; # = mg/kg/day; $ = follow up since adding TPM bance was complained most frequently. Nonetheless, 69% in total felt better after TPM add-on therapy.
Treatment-emergent adverse events
Sixteen (73%) of our patients reported treatment-emergent adverse events, 13 of them had marked events ( Table 2 ). Only two (9%), however, discontinued TPM therapy because of adverse events: persistently elevated liver enzyme in one, and severely reduced appetite in the other. Hypohidrosis was the most common side effect reported in the present study. Nearly half (41%) of our patients had this problem, more notable in summer. 
Discussion
Studies on the efficacy of new AEDs in children with CNS anomalies are limited [16] [17] [18] . Lamotrigine (LTG) had been used as adjunctive therapy in patients with refractory epilepsy and mental retardation [16] . Only 28% of patients had more than 50% reduction in seizure frequency, and 11% became seizure free. Another study in adult patients with learning disability and resistant epilepsy showed responder rates of 50% for gabapentin and 48.6% for LTG [17] . Vigabatrin (VGB) used in patients with refractory epilepsy and mental retardation showed responder rates of 42% at three months and 33% at one year [18] . In the present study, TPM add-on therapy showed equal or better results. However, compared to patients with mental retardation or learning disability, in whom the responder rates were reported to be as high as 60-70% [19, 20] , TPM was less effective in children with CNS anomalies.
Although many studies were performed in adult patients, clinical studies on the efficacy of TPM in children are limited [6, 8, 9, 11, 21, 22] . In adult patients, the percentages of responders were 80% in secondarily generalized seizures, 71% in simple partial motor seizures, and 56% in complex partial seizures [23] . Reviewing the literature, the percentages of responders in children ranged from 39% to 64% in partial-onset seizures [6, 21] , 45% in secondarily generalized seizures [6] , 50% in primary generalized tonic-clonic seizures [7] , and 54% in refractory epilepsy [22] . While the responder rates in secondarily and symptomatic generalized epilepsy in the present study (51% and 38%, respectively) were similar to those of previous studies, all three patients with other SPE were "responders". Two of the three patients with other SPE were seizure free, and the remaining one had more than 50% reduction of seizure frequency. Although patients with Lennox-Gastaut syndrome responded very well to TPM in a past study [24] , no patient had more than 50% seizure reduction in the present study. Only Patient 17 became seizure free temporarily after adding TPM; unfortunately, seizures recurred during follow-up. The discrepancy in response rate between previous studies and ours might derive from the underlying disease: our patients had CNS malformations, while patients with 'significant acute or chronic confounding disease' were excluded in previous study [24] .
As previously reported, the response rates to treatment in patients with infantile spasms were 50-67% to ACTH and 40-70% to vigabatrin [8] , which were comparable to the present study (responder rate, 63%). However, all of our eight patients with infantile spasms had CNS anomalies and are thus "symptomatic", while those of previous comparable studies included cryptogenic or idiopathic as well as symptomatic patients [8, 15] . As symptomatic infantile spasms responded less favorably to AED therapy than idiopathic and cryptogenic infantile spasms [25] , the responder rate of TPM in patients with cryptogenic infantile spasms may be higher.
Sixteen (73%) of our patients reported treatment-emergent adverse events (Table 2) , and the frequencies of most of the events were similar to those reported in the literature [10] .
Only two (9%) patients discontinued TPM therapy because of adverse events, and 73-86% patients felt no impact of TPM therapy on their health-related quality of life ( Figure  3 ). This discrepancy between high frequencies of adverse events and little impact on quality of life was attributed to the following reasons. First, most of the adverse events were temporary and resolved over time. Second, the improvement of seizure control outweighed the minor adverse events in the evaluation of quality of life. Nonetheless, polytherapy and the patients' underlying CNS abnormalities may contribute to the high incidence of adverse events.
Oligohidrosis or hypohidrosis has been reported in patients taking TPM [26] [27] [28] . The incidence of hypohidrosis in the present study, however, was higher. One of the reasons was related to methodology: we inquired parents actively rather than letting them report by themselves. Some parents might not take notice of mild hypohidrosis, which did not affect the patients' daily life. The other reason was attributed to the environmental temperature: the higher the temperature, the more remarkable the oligohidrosis. The subtropical climate in Taiwan makes the incidence higher than other previous western studies [26] [27] [28] . Without objective measurement, hypohidrosis is not noticed clinically until facial flush and hyperthermia appear. De Carolis P et al [27] proposed that the underlying mechanism could be related to a carbonic anhydrase block at the level of sweat gland. This adverse effect of TPM therapy, however, was transient and reversible.
In conclusion, TPM is proven to be an effective add-on AED for children with epilepsies and CNS anomalies in the present study; the overall responder rate was 54%. No significant impact on patients' quality of life was noted during treatment. Hypohidrosis was the most common adverse effect noted in subtropical countries like Taiwan, and doctors should inform the parents about this in advance.
